---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-007916"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:40:23.645366+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Eton Q4 2022: product revenue +220% YoY, net income positive; CEO sees 2023 doubling

## Summary
- Q4 net revenue $8.5M (incl. $5M milestone); product/royalty $3.5M (+220% YoY, +9% QoQ).
- Net income $0.9M ($0.04 diluted EPS); gross profit $6.4M; cash $16.3M at Dec 31, 2022.
- Eighth straight sequential product revenue growth; CEO expects at least 2x product/royalty revenue in 2023.
- Expanded rare disease sales force to 12 specialists; Betaine launch imminent; Dehydrated Alcohol NDA action date June 27, 2023.
- Acquired ET-600 (rare pediatric endocrinology); ET-400 NDA expected by end of 2023.

## SEC filing metadata
- accession: 0001493152-23-007916
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/0001493152-23-007916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-007916
- JSON: https://secwatch.observer/filing/0001493152-23-007916.json
- Plain text: https://secwatch.observer/filing/0001493152-23-007916.txt

## Key facts
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported financial results for fourth quarter ended December 31, 2022.
  - Period: fourth quarter ended December 31, 2022
  - Result: reported results
  source text: Net income for the fourth quarter of 2022 was $0.9 million or $0.04 per basic and diluted share compared to a net income of $1.0 million or $0.04 per diluted share in the prior year period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/0001493152-23-007916-index.htm
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported fourth quarter and year ended December 31, 2022 results: revenue $8.5 million, net income $0.9 million, EPS $0.04 per basic and diluted share.
  - Period: fourth quarter and year ended December 31, 2022
  - Revenue: $8.5 million
  - Net income: $0.9 million
  - EPS: $0.04 per basic and diluted share
  - Result: reported results
  source text: Net revenues for the fourth quarter of 2022 were $8.5 million compared with $6.1 million in the prior year period
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000149315223007916/0001493152-23-007916-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.